Chabiotech Co.,Ltd.

KOSDAQ:A085660 Stock Report

Market Cap: ₩946.1b

ChabiotechLtd Past Earnings Performance

Past criteria checks 0/6

ChabiotechLtd's earnings have been declining at an average annual rate of -54%, while the Healthcare industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 13.3% per year.

Key information

-54.0%

Earnings growth rate

-53.8%

EPS growth rate

Healthcare Industry Growth34.2%
Revenue growth rate13.3%
Return on equity-2.9%
Net Margin-2.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Aug 07
Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

Mar 01
Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

Jan 25
If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About

Dec 21
The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About

Revenue & Expenses Breakdown

How ChabiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A085660 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24974,803-22,482239,14615,773
31 Mar 24949,922-27,916239,14314,838
31 Dec 23953,951-8,431234,34014,614
30 Sep 23942,431-32,667236,33614,455
30 Jun 23921,073-40,063228,95113,999
31 Mar 23892,981-37,037221,26414,586
31 Dec 22844,583-47,543214,93714,359
30 Sep 22808,777-4,922197,99613,787
30 Jun 22779,374602182,06913,369
31 Mar 22747,666-21,366183,23412,791
31 Dec 21727,476-13,968173,41413,050
30 Sep 21704,072-26,755167,57013,401
30 Jun 21694,812-31,561171,88113,895
31 Mar 21677,277-16,194162,58813,453
31 Dec 20664,717-18,658161,03013,457
30 Sep 20655,853-7,667152,99411,890
30 Jun 20590,893-8,520150,87212,206
31 Mar 20565,52949,125146,29212,234
31 Dec 19534,61246,375144,87711,328
30 Sep 19500,91046,386148,32810,419
30 Jun 19515,23251,595142,6568,408
31 Mar 19502,20119,231141,1647,464
31 Dec 18488,60024,698128,3416,771
30 Sep 18502,3601,516123,7336,202
30 Jun 18467,869-12,462118,9577,391
31 Mar 18435,256-37,872107,6898,690
31 Dec 17417,460-45,585112,5149,462
30 Sep 17402,155-20,436105,05415,492
30 Jun 17416,750-9,272103,46713,124
31 Mar 17434,6691,02499,21710,609
31 Dec 16449,26111,44898,6978,876
30 Sep 16428,117-6,336143,8943,503
30 Jun 16423,770-8,274126,7773,446
31 Mar 16410,812-10,394111,8443,448
31 Dec 15393,782-14,95695,6043,373
30 Sep 15424,0741,80532,3162,298
30 Jun 15386,370-56229,1242,085
31 Mar 15361,625-2,25733,9881,746
31 Dec 14345,345-4,72135,4171,569
30 Sep 14298,626-12,15742,7111,203
30 Jun 14323,263-5,31248,8461,126
31 Mar 14370,7494,71250,281958
31 Dec 13386,83511,30853,8521,018

Quality Earnings: A085660 is currently unprofitable.

Growing Profit Margin: A085660 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A085660 is unprofitable, and losses have increased over the past 5 years at a rate of 54% per year.

Accelerating Growth: Unable to compare A085660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A085660 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6.4%).


Return on Equity

High ROE: A085660 has a negative Return on Equity (-2.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies